Arrowhead Pharmaceuticals, Inc. (ARWR) has begun dosing the first participants in a Phase 1/2a study of ARO‑DIMER‑PA, an investigational RNA interference (RNAi) therapeutic that simultaneously silences proprotein convertase subtilisin‑kexin 9 (PCSK9) and apolipoprotein C3 (APOC3). The dual‑target design is intended to lower both low‑density lipoprotein cholesterol and triglycerides in patients with mixed hyperlipidemia, a condition that remains a major residual risk factor for atherosclerotic cardiovascular disease.
The study, registered as NCT07223658, plans to enroll up to 78 adults and will progress through a single‑dose escalation phase followed by a multiple‑dose phase. Arrowhead’s TRiM platform, which enables multi‑tissue delivery, underpins the therapy’s quarterly dosing goal and represents the first dual‑functional RNAi candidate in the company’s portfolio.
Arrowhead’s financial trajectory has strengthened in the past year: revenue rose to $829 million in fiscal 2025, largely driven by licensing and collaboration agreements, while the net loss narrowed to $2 million from $599 million in fiscal 2024. The recent FDA approval of REDEMPLO (plozasiran) for familial chylomicronemia syndrome validated the TRiM platform and positioned Arrowhead as a commercial‑stage RNAi company, giving the ARO‑DIMER‑PA program additional credibility and investor confidence.
Analysts have responded positively to the trial launch, raising price targets for ARWR to $100–$110 and upgrading the consensus rating to “Buy.” The upgrades reflect the company’s pipeline expansion, the commercial success of REDEMPLO, and the improved financial health that supports continued R&D investment.
CEO Christopher Anzalone said, “ARO‑DIMER‑PA is designed to silence both PCSK9 and APOC3, two targets with strong clinical validation for reducing LDL‑cholesterol, triglycerides, and total atherogenic lipoproteins. The dual‑target approach could provide a single, quarterly treatment for patients who remain at risk despite current monotherapies.”
The trial’s success could open a sizable mixed‑hyperlipidemia market, estimated to grow from $23.8 billion in 2024 to nearly $30 billion by 2033. By addressing both cholesterol and triglyceride abnormalities, Arrowhead may capture patients who are underserved by existing therapies, positioning the company for a broader commercial footprint and a stronger competitive stance in the cardiovascular therapeutics arena.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.